These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21958962)

  • 1. Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.
    Coppus AM; Schuur M; Vergeer J; Janssens AC; Oostra BA; Verbeek MM; van Duijn CM
    Neurobiol Aging; 2012 Sep; 33(9):1988-94. PubMed ID: 21958962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neopterin and the risk of dementia in persons with Down syndrome.
    Coppus AM; Fekkes D; Verhoeven WM; Evenhuis HM; van Duijn CM
    Neurosci Lett; 2009 Jul; 458(2):60-4. PubMed ID: 19442877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid beta concentrations in older people with Down syndrome and dementia.
    Jones EL; Hanney M; Francis PT; Ballard CG
    Neurosci Lett; 2009 Feb; 451(2):162-4. PubMed ID: 19111900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.
    Schupf N; Patel B; Silverman W; Zigman WB; Zhong N; Tycko B; Mehta PD; Mayeux R
    Neurosci Lett; 2001 Apr; 301(3):199-203. PubMed ID: 11257432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.
    Prasher VP; Sajith SG; Mehta P; Zigman WB; Schupf N
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):202-7. PubMed ID: 19513990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.
    Hansson O; Stomrud E; Vanmechelen E; Östling S; Gustafson DR; Zetterberg H; Blennow K; Skoog I
    J Alzheimers Dis; 2012; 28(1):231-8. PubMed ID: 21955816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.
    Le Bastard N; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2010; 21(1):291-301. PubMed ID: 20421698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease.
    González-Martínez Á; Rosado B; Pesini P; Suárez ML; Santamarina G; García-Belenguer S; Villegas A; Monleón I; Sarasa M
    Exp Gerontol; 2011 Jul; 46(7):590-6. PubMed ID: 21377518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total serum cholesterol levels and Alzheimer's dementia in patients with Down syndrome.
    Prasher VP; Airuehia E; Patel A; Haque MS
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):937-42. PubMed ID: 18395888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.
    Lewczuk P; Kornhuber J; Vanmechelen E; Peters O; Heuser I; Maier W; Jessen F; Bürger K; Hampel H; Frölich L; Henn F; Falkai P; Rüther E; Jahn H; Luckhaus Ch; Perneczky R; Schmidtke K; Schröder J; Kessler H; Pantel J; Gertz HJ; Vanderstichele H; de Meyer G; Shapiro F; Wolf S; Bibl M; Wiltfang J
    Exp Neurol; 2010 Jun; 223(2):366-70. PubMed ID: 19664622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.
    Chouraki V; Beiser A; Younkin L; Preis SR; Weinstein G; Hansson O; Skoog I; Lambert JC; Au R; Launer L; Wolf PA; Younkin S; Seshadri S
    Alzheimers Dement; 2015 Mar; 11(3):249-57.e1. PubMed ID: 25217292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
    Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
    Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.
    Pannee J; Törnqvist U; Westerlund A; Ingelsson M; Lannfelt L; Brinkmalm G; Persson R; Gobom J; Svensson J; Johansson P; Zetterberg H; Blennow K; Portelius E
    Neurosci Lett; 2014 Jun; 573():7-12. PubMed ID: 24796810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
    Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome.
    Tokuda T; Fukushima T; Ikeda S; Sekijima Y; Shoji S; Yanagisawa N; Tamaoka A
    Ann Neurol; 1997 Feb; 41(2):271-3. PubMed ID: 9029078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
    Mehta PD; Capone G; Jewell A; Freedland RL
    J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased myeloperoxidase plasma levels in patients with Alzheimer's disease.
    Tzikas S; Schlak D; Sopova K; Gatsiou A; Stakos D; Stamatelopoulos K; Stellos K; Laske C
    J Alzheimers Dis; 2014; 39(3):557-64. PubMed ID: 24217274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.